Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%

Reuters11-11

Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%

Xtant Medical Holdings Inc. reported third quarter 2025 revenue of $33.3 million, an increase of 19% compared to the same period last year. Gross margin reached 66.1%, up from 58.4% in the prior year quarter. The company delivered positive net income, adjusted EBITDA, and operating cash flow for the quarter. As of September 30, 2025, cash and cash equivalents stood at $10.6 million, compared to $6.2 million as of December 31, 2024. Xtant reiterated its full-year 2025 revenue guidance of $131 million to $135 million, representing projected growth of 11% to 15% over 2024. The company also announced the anticipated sale of certain hardware assets and international businesses to Companion Spine, expected to close by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA20100) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582388478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582388478","market":"us","top_or_hot":-1,"title":"Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XTNT\">Xtant Medical Holdings Inc</a>. reported third quarter 2025 revenue of $33.3 million, an increase of 19% compared to the same period last year. Gross margin reached 66.1%, up from 58.4% in the prior year quarter. The company delivered positive net income, adjusted EBITDA, and operating cash flow for the quarter. As of September 30, 2025, cash and cash equivalents stood at $10.6 million, compared to $6.2 million as of December 31, 2024. Xtant reiterated its full-year 2025 revenue guidance of $131 million to $135 million, representing projected growth of 11% to 15% over 2024. The company also announced the anticipated sale of certain hardware assets and international businesses to Companion Spine, expected to close by year-end.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA20100) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XTNT\">Xtant Medical Holdings Inc</a>. reported third quarter 2025 revenue of $33.3 million, an increase of 19% compared to the same period last year. Gross margin reached 66.1%, up from 58.4% in the prior year quarter. The company delivered positive net income, adjusted EBITDA, and operating cash flow for the quarter. As of September 30, 2025, cash and cash equivalents stood at $10.6 million, compared to $6.2 million as of December 31, 2024. Xtant reiterated its full-year 2025 revenue guidance of $131 million to $135 million, representing projected growth of 11% to 15% over 2024. The company also announced the anticipated sale of certain hardware assets and international businesses to Companion Spine, expected to close by year-end.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA20100) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XTNT","symbol_name":"Xtant Medical Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbd4CM:1","article_id":"2582388478","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582388478","pubTimestamp":1762810155,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xtant Medical Holdings Inc. reported third quarter 2025 revenue of $33.3 million, an increase of 19% compared to the same period last year. Gross margin reached 66.1%, up from 58.4% in the prior year quarter. The company delivered positive net income, adjusted EBITDA, and operating cash flow for the quarter. As of September 30, 2025, cash and cash equivalents stood at $10.6 million, compared to $6.2 million as of December 31, 2024. Xtant reiterated its full-year 2025 revenue guidance of $131 million to $135 million, representing projected growth of 11% to 15% over 2024. The company also announced the anticipated sale of certain hardware assets and international businesses to Companion Spine, expected to close by year-end.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XTNT":"Xtant Medical Holdings Inc","BK4198":"医疗保健用品"},"translate_title":"Xtant Medical Holdings报告第三季度收入为3330万美元，增长19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XTNT":0.9},"content_text":"Xtant Medical Holdings Reports Q3 Revenue of $33.3 Million, Up 19%\n    \n\nXtant Medical Holdings Inc. reported third quarter 2025 revenue of $33.3 million, an increase of 19% compared to the same period last year. Gross margin reached 66.1%, up from 58.4% in the prior year quarter. The company delivered positive net income, adjusted EBITDA, and operating cash flow for the quarter. As of September 30, 2025, cash and cash equivalents stood at $10.6 million, compared to $6.2 million as of December 31, 2024. Xtant reiterated its full-year 2025 revenue guidance of $131 million to $135 million, representing projected growth of 11% to 15% over 2024. The company also announced the anticipated sale of certain hardware assets and international businesses to Companion Spine, expected to close by year-end.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA20100) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582388478","isCrawlerRequest":true}